Search results
Results from the WOW.Com Content Network
Endo is one of the companies named in lawsuits by the states of Ohio, [42] Missouri and Mississippi [43] as responsible for the US opioid epidemic. Its 10-K statement indicates that a majority of the company's US revenue in 2016 was derived from the sale of prescription pain killers, predominantly opioids. [44]
This is the list of Schedule I controlled substances in the United States as defined by the Controlled Substances Act. [1] The following findings are required for substances to be placed in this schedule: [2] The drug or other substance has a high potential for abuse.
opiate Codeine [2] 9334 opiate Dihydroetorphine [3] 9190 opiate Ethylmorphine [2] 9059 opiate Etorphine hydrochloride [4] 9640 opiate Granulated opium [2] 9193 opiate Hydrocodone [2] 9150 opiate Hydromorphone [2] 9260 opiate Metopon [2] 9300 opiate Morphine [2] 9668 opiate Noroxymorphone [5] 9610 opiate Opium extracts [2] 9620 opiate Opium ...
The law (TN Code 53-11-311) that prevents nurse practitioners (NPs) or physician assistants (PAs) from prescribing more than 16 milligrams of buprenorphine-naloxone daily (despite standard dosing ...
McKinsey & Co has agreed to pay $650 million to resolve a US Department of Justice investigation into the consulting firm’s work advising opioid manufacturer OxyContin maker Purdue Pharma on how ...
Carbonate derivatives of 14β-hydroxycodeine "viz., 14β-hydroxy-6-O-(methoxycarbonyl)codeine, 6-O-methoxycarbonyl-14β-(methoxycarbonyloxy)codeine, and 14β-acetoxy-6-O-methoxy-carbonylcodeine, potential substrates for ring C modification in morphinane (sic) alkaloids, were synthesized for the first time."
McKinsey & Company consulting firm has agreed to pay $650 million to settle a federal investigation into its work to help opioids manufacturer Purdue Pharma boost the sales of the highly addictive ...
In the same month, it also posted approximately $1.7 million in revenue, in large part drawn from its licensing for its European intellectual property rights for Probuphine to the Italian pharmaceutical company Molteni - a leading European opioid manufacturer and also a subsidiary of the German Pharmaceutical juggernaut Merck Group.